AltaValve Early Feasibility Study Protocol
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03997305 |
Recruitment Status :
Recruiting
First Posted : June 25, 2019
Last Update Posted : November 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mitral Regurgitation Mitral Insufficiency Mitral Valve Incompetence Mitral Valve Regurgitation Mitral Incompetence | Device: AltaValve | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 15 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | AltaValve Early Feasibility Study Protocol |
Actual Study Start Date : | December 4, 2019 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | September 2025 |
- Device: AltaValve
Transcatheter Mitral Valve Replacement
- Major Adverse Cardiac Event [ Time Frame: 30 days ]Cardiac death, stroke, mitral valve related repeated intervention
- Technical success [ Time Frame: Index procedure completion (Day 0) ]Technical Success per MVARC criteria
- Procedural success [ Time Frame: 30 days ]Device success and absence of major device or procedure related serious adverse events
- Device success [ Time Frame: 30 days ]Device Success per MVARC criteria
- Change in MR grade [ Time Frame: 30 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects ≥ 18 years of age.
- Subjects symptomatic New York Heart Association (NYHA) II-IV.
- Subjects with severe MR as documented by echo.
- Subjects who are at high risk for open-heart surgery as documented by the health care professional (e.g., Heart Team consisting of cardiac surgeon and interventional cardiologist in United States).
Abbreviated Exclusion Criteria:
- Inability to understand the study or a history of non-compliance with medical advice.
- Unwilling or unable to sign the Informed Consent Form (ICF).
- History of any cognitive or mental health status that would interfere with study participation.
- Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.)).
- Female subjects who are pregnant or planning to become pregnant within the study period.
- Known hypersensitivity or contraindication to aspirin, heparin, or Warfarin without adequate alternative medications.
- Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately medicated.
- Known hypersensitivity to contrast media that cannot be adequately medicated.
- Evidence of current Left Ventricular Ejection Fraction (LVEF) ≤30% (where current is defined as the latest LVEF measurement completed within 90 days prior to the index procedure).
- Concurrent medical condition with a life expectancy of less than 12 months.
- Prior mitral valve repair/replacement (excluding prior surgical mitral valve repair, annuloplasty, or MitraClip not interfering with AltaValve placement).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03997305
Contact: Kevin Booth | 580-399-3767 | AltaValveEFS@4CMed.com |
United States, California | |
Los Robles Regional Medical Center | Recruiting |
Thousand Oaks, California, United States, 91360 | |
Contact: Mane Arabyan 805-796-3746 Mane.Arabyan@hcahealthcare.com | |
Principal Investigator: Saibal Kar, MD, FACC, FSCAI | |
Principal Investigator: Gregory Fontana, MD, FACS, FACC | |
United States, District of Columbia | |
MedStar Washington Hospital | Recruiting |
Washington, District of Columbia, United States, 20010 | |
Contact: Erin C Collins, MPH 202-877-6622 erin.c.collins@medstar.net | |
Principal Investigator: Ron Waksman, MD, FACS | |
Principal Investigator: Christian Shults, MD, FACS | |
United States, Georgia | |
Emory University | Recruiting |
Atlanta, Georgia, United States, 30308 | |
Contact: Elizabeth Charles 404-686-1249 elizabeth.z.charles@emory.edu | |
Principal Investigator: Gaetano Paone, MD, MHSA | |
Principal Investigator: George Hanzel, MD, FACC | |
United States, Louisiana | |
Cardiovascular Institute of the South | Recruiting |
Houma, Louisiana, United States, 70360 | |
Contact: Jennifer Aucoin, LPN Jennifer.Aucoin@cardio.com | |
Principal Investigator: Peter Fail, MD, FACC | |
Principal Investigator: Donald Netherland, MD | |
Principal Investigator: Stephen Ball, MD | |
United States, Minnesota | |
CentraCare Hearth and Vascular Center | Recruiting |
Saint Cloud, Minnesota, United States, 56303 | |
Contact: Peggy Dahl, RN 320-251-2700 ext 52187 dahlp@centracare.com | |
Contact: Jennifer Humbert, BSN 320-251-2800 ext 57560 humbertj@centracare.com | |
Principal Investigator: Thom Dahle, MD, FACC | |
Principal Investigator: Daren Danielson, MD | |
United States, New Jersey | |
Morristown Medical Center | Recruiting |
Morristown, New Jersey, United States, 07960 | |
Contact: Catherine VanZile 201-787-2254 catherine.vanzile@atlantichealth.org | |
Principal Investigator: Philippe Genereux, MD | |
Principal Investigator: John Brown III, MD | |
United States, New York | |
St. Francis Hospital | Recruiting |
Roslyn, New York, United States, 11576 | |
Contact: Lyn Santiago, RN lyn.santiago@chsli.org | |
Principal Investigator: George A Petrossian, MD | |
Principal Investigator: Newell B Robinson, MD | |
United States, North Carolina | |
Atrium Health | Recruiting |
Charlotte, North Carolina, United States, 28203 | |
Contact: Bandaa Setliff, RN bandaa.setliff@atriumhealth.org | |
Principal Investigator: Michael Rinaldi, MD, FACC | |
Principal Investigator: Eric Skipper, MD | |
United States, Ohio | |
The Lindner Research Center at The Christ Hospital | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
Contact: Julianne O'Brien 513-585-1777 | |
Principal Investigator: Joseph Choo, MD, FACC | |
Principal Investigator: J Michael Smith, MD | |
United States, Oklahoma | |
Oklahoma Heart Hospital | Recruiting |
Oklahoma City, Oklahoma, United States, 73135 | |
Contact: Julie White 405-628-6865 juliewhite@okheart.com | |
Principal Investigator: Bruce Cannon, MD | |
Principal Investigator: Naeem Tahirkheli, MD | |
United States, Tennessee | |
Baptist Memorial Hospital - Memphis | Recruiting |
Memphis, Tennessee, United States, 38120 | |
Contact: Mary Thurmond 901-747-1262 mary@cvsclinic.com | |
Principal Investigator: H. Edward Grant Jr., MD | |
Principal Investigator: Basil M. Paulus, MD | |
United States, Texas | |
Houston Methodist Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Lisa Green, RN, BSN 713-441-3629 lmgreen@houstonmethodist.org | |
Principal Investigator: Sachin Goel, MD, FACC | |
Principal Investigator: Moritz Wyler von Ballmoos, MD, FACC | |
Baylor Scott & White | Recruiting |
Plano, Texas, United States, 75093 | |
Contact: Alexandra Finley 469-814-4235 Alexandra.Finley@BSWHealth.org | |
Principal Investigator: Molly Szerlip, MD, FACC, FSCAI | |
Principal Investigator: Timothy George, MD |
Principal Investigator: | Philippe Genereux, MD | Morristown Medical Center | |
Principal Investigator: | Vinayak Bapat, MD | Allina Health System |
Responsible Party: | 4C Medical Technologies, Inc. |
ClinicalTrials.gov Identifier: | NCT03997305 |
Other Study ID Numbers: |
1890 |
First Posted: | June 25, 2019 Key Record Dates |
Last Update Posted: | November 17, 2022 |
Last Verified: | November 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Mitral Regurgitation TMVR Functional Regurgitation Degenerative Regurgitation |
Transcathether Mitral Valve Replacement Primary Regurgitation Secondary Regurgitation |
Mitral Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |